What does this research mean for the field?

In patients with rheumatoid arthritis, risk factors for chronic kidney disease progression depend on baseline renal function, with residual inflammation driving progression in those with preserved eGFR, and proteinuria, albuminuria, and anemia being more significant in those with reduced eGFR. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the relative contributions of systemic inflammatory markers and traditional renal risk factors to the five-year progression of chronic kidney disease in patients with rheumatoid arthritis.

August 30, 2026Clinical and Experimental NephrologyOpen Access

Inflammatory and traditional risk factors associated with the progression of chronic kidney disease in patients with rheumatoid arthritis

View Full Paper

Ask AI

Bookmark

Authors

MSMasafumi Sugiyama SMSayo Morita TTTakashi Tsuchimoto

Discussion

Member takes

Overview

Retrospective cohort study finds baseline inflammation and kidney damage drive renal decline in rheumatoid arthritis, highlighting stage-specific monitoring needs.

Key Points

To evaluate the relative contributions of systemic inflammatory markers and traditional renal risk factors to the five-year progression of chronic kidney disease in patients with rheumatoid arthritis.
Retrospective analysis of 601 patients with rheumatoid arthritis evaluated for kidney function via creatinine-based estimated glomerular filtration rate (eGFR) and urinary albumin.
Identified risk factors for KDIGO high-risk categories and five-year chronic kidney disease stage progression using multivariable logistic regression and Cox proportional hazards models.
Utilized propensity score matching to assess the safety and association of methotrexate therapy with kidney disease progression.
Chronic kidney disease stage progression occurred in 106 of 601 patients, with older age, reduced baseline eGFR, anemia, and CRP ≥0.5 mg/dL acting as independent risk factors.
Predictors of progression varied by initial kidney status: CRP ≥0.5 mg/dL independently predicted decline in patients with eGFR ≥60 mL/min/1.73 m², whereas proteinuria and albuminuria were significant drivers in those with eGFR <60 mL/min/1.73 m².
Propensity score-matched analyses demonstrated no association between methotrexate use and an increased risk of chronic kidney disease stage progression.

Cite This Study

Sugiyama et al. (2026) studied this question.

synapsesocial.com/papers/6a941ce46c1a8fb52e79e859 https://doi.org/10.1007/s10157-026-02937-3

View Full Paper

Ask AI

Bookmark

August 30, 2026Clinical and Experimental NephrologyOpen Access

Inflammatory and traditional risk factors associated with the progression of chronic kidney disease in patients with rheumatoid arthritis

View Full Paper

Ask AI

Bookmark

Authors

MSMasafumi Sugiyama SMSayo Morita TTTakashi Tsuchimoto

Discussion

Member takes

Overview

Retrospective cohort study finds baseline inflammation and kidney damage drive renal decline in rheumatoid arthritis, highlighting stage-specific monitoring needs.

Key Points

To evaluate the relative contributions of systemic inflammatory markers and traditional renal risk factors to the five-year progression of chronic kidney disease in patients with rheumatoid arthritis.
Retrospective analysis of 601 patients with rheumatoid arthritis evaluated for kidney function via creatinine-based estimated glomerular filtration rate (eGFR) and urinary albumin.
Identified risk factors for KDIGO high-risk categories and five-year chronic kidney disease stage progression using multivariable logistic regression and Cox proportional hazards models.
Utilized propensity score matching to assess the safety and association of methotrexate therapy with kidney disease progression.
Chronic kidney disease stage progression occurred in 106 of 601 patients, with older age, reduced baseline eGFR, anemia, and CRP ≥0.5 mg/dL acting as independent risk factors.
Predictors of progression varied by initial kidney status: CRP ≥0.5 mg/dL independently predicted decline in patients with eGFR ≥60 mL/min/1.73 m², whereas proteinuria and albuminuria were significant drivers in those with eGFR <60 mL/min/1.73 m².
Propensity score-matched analyses demonstrated no association between methotrexate use and an increased risk of chronic kidney disease stage progression.

Cite This Study

Sugiyama et al. (2026) studied this question.

synapsesocial.com/papers/6a941ce46c1a8fb52e79e859 https://doi.org/10.1007/s10157-026-02937-3

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark